Mineralocorticoid Receptor Antagonism — FINDing Another Benefit

New England Journal of Medicine · Published 2026-08-05 · DOI 10.1056/nejme2608321

Authors (1)

Robert Toto

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Toto, R. (2026). Mineralocorticoid Receptor Antagonism — FINDing Another Benefit. New England Journal of Medicine. https://doi.org/10.1056/nejme2608321

Related articles

• Health Care–Associated Infections in U.S. Hospitals, 2023 versus 2015 · New England Journal of Medicine · 2026 · Same journal
• Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment · New England Journal of Medicine · 2026 · Same journal
• Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer · New England Journal of Medicine · 2026 · Same journal
• Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma · New England Journal of Medicine · 2026 · Same journal
• Transdermal Estradiol Patches in Prostate Cancer · New England Journal of Medicine · 2026 · Same journal
• Left Ventricular Unloading in High-Risk PCI · New England Journal of Medicine · 2026 · Same journal
• Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma · New England Journal of Medicine · 2026 · Same journal
• Koebner Phenomenon from Wet Cupping · New England Journal of Medicine · 2026 · Same journal
• More on Digital Twin–Guided Ablation for Ventricular Tachycardia · New England Journal of Medicine · 2026 · Same journal
• Cross-Correction in HSC Gene Therapy for Metachromatic Leukodystrophy · New England Journal of Medicine · 2026 · Same journal